Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axcella Health Inc.AXLA · Entity 116059 | Director | May 20, 2021 | May 24, 2021 |
| Seres Therapeutics, Inc.MCRB · Entity 7191 | Director | June 22, 2023 | June 23, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axcella Health Inc.
Report date May 20, 2021 · Filed May 24, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.24 · Expires 2031-05-19 | Direct | 20,000 |
Reported balance
After 2021-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-20 · Grant · Acquired 20,000 · Balance 20,000 F1: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting.
Seres Therapeutics, Inc.
Report date June 22, 2023 · Filed June 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.46 · Expires 2033-06-21 | Direct | 35,000 |
Reported balance
After 2023-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-22 · Grant · Acquired 35,000 · Balance 35,000 F1: The option vests in full on the earlier of June 22, 2024 or the day immediately prior to the company's 2024 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of June 22, 2024 or the day immediately prior to the company's 2024 annual meeting of shareholders.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aimmune Therapeutics, Inc.
Report date October 13, 2020 · Filed October 14, 2020
Section 16 reporting ended · disclosed 2020-10-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2020-10-13 · Other · Disposed 10,192 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., and SPN MergerSub, Inc (the "Merger Agreement"), the securities were cancelled and will cease to exist, and no consideration was delivered in exchange for such cancellation. |
| Common Stock, $0.0001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2020-10-13 · Disposition to issuer · Disposed 7,840 · Balance 0 F2: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) $34.50 per share (the "Offer Price") multiplied by (ii) the number of shares of common stock subject to the RSU. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.90 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-13 · Disposition to issuer · Disposed 39,510 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.26 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-10-13 · Disposition to issuer · Disposed 17,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.79 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-13 · Disposition to issuer · Disposed 7,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.90 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-10-13 · Disposition to issuer · Disposed 11,432 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.11 | Direct | 0 |
Reported balance
After 2020-10-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-10-13 · Disposition to issuer · Disposed 15,398 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., and SPN MergerSub, Inc (the "Merger Agreement"), the securities were cancelled and will cease to exist, and no consideration was delivered in exchange for such cancellation.
F2: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) $34.50 per share (the "Offer Price") multiplied by (ii) the number of shares of common stock subject to the RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2023 Filed Jun 23, 2023 21:24 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0000899243-23-016398 · doc4.xml · derivative · entry 1 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The option vests in full on the earlier of June 22, 2024 or the day immediately prior to the company's 2024 annual meeting of shareholders. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:31 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0000899243-22-023979 · doc4.xml · derivative · entry 1 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2032-06-21 F1 · derivative.exercise_date: The option vests in full on the earlier of June 22, 2023 or the day immediately prior to the company's 2023 annual meeting of shareholders. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 23,000 | $0.00 Strike: $19.74 | $0.00 |
DisclosureSEC source: 0000899243-21-024994 · doc4.xml · derivative · entry 1 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: The option vests in full on the earlier of June 16, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. Read SEC document |
| May 20, 2021 Filed May 24, 2021 17:16 UTC | Axcella Health Inc. AXLA · Entity 116059 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001104659-21-071340 · tm2116997-4_4seq1.xml · derivative · entry 1 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-19 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Disposition to issuerStock Option (right to buy) · Derivative | 15,398 | $17.39 Strike: $17.11 | $267,771.22 |
DisclosureSEC source: 0000899243-20-028179 · doc4.xml · derivative · entry 7 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,398 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Disposition to issuerStock Option (right to buy) · Derivative | 11,432 | $14.60 Strike: $19.90 | $166,907.20 |
DisclosureSEC source: 0000899243-20-028179 · doc4.xml · derivative · entry 6 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,432 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Disposition to issuerStock Option (right to buy) · Derivative | 7,500 | $1.71 Strike: $32.79 | $12,825.00 |
DisclosureSEC source: 0000899243-20-028179 · doc4.xml · derivative · entry 5 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Disposition to issuerStock Option (right to buy) · Derivative | 17,500 | $16.24 Strike: $18.26 | $284,200.00 |
DisclosureSEC source: 0000899243-20-028179 · doc4.xml · derivative · entry 4 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Disposition to issuerStock Option (right to buy) · Derivative | 39,510 | $9.60 Strike: $24.90 | $379,296.00 |
DisclosureSEC source: 0000899243-20-028179 · doc4.xml · derivative · entry 3 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,510 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | Disposition to issuerCommon Stock, $0.0001 par value | 7,840 | $34.50 | $270,480.00 |
DisclosureSEC source: 0000899243-20-028179 · doc4.xml · nonDerivative · entry 2 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) $34.50 per share (the "Offer Price") multiplied by (ii) the number of shares of common stock subject to the RSU. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 16:15 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | OtherCommon Stock, $0.0001 par value | 10,192 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-028179 · doc4.xml · nonDerivative · entry 1 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., and SPN MergerSub, Inc (the "Merger Agreement"), the securities were cancelled and will cease to exist, and no consideration was delivered in exchange for such cancellation. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 20:09 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $4.40 | $0.00 |
DisclosureSEC source: 0000899243-20-017347 · doc4.xml · derivative · entry 1 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: The option vests in full on the earlier of June 18, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders. Read SEC document |
| May 27, 2020 Filed May 29, 2020 19:17 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantStock Option (right to buy) · Derivative | 15,398 | $0.00 Strike: $17.11 | $0.00 |
DisclosureSEC source: 0000899243-20-014619 · doc4.xml · derivative · entry 2 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,398 Underlying: Common Stock · 15,398 shares Expires 2030-05-26 F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 27, 2020 Filed May 29, 2020 19:17 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantCommon Stock, $0.0001 par value | 7,840 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-014619 · doc4.xml · nonDerivative · entry 1 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,032 F1 · shares: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2021 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 20, 2020 Filed May 22, 2020 17:16 UTC | Axcella Health Inc. AXLA · Entity 116059 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001104659-20-065466 · a4.xml · derivative · entry 1 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2030-05-19 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 20:12 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.83 | $0.00 |
DisclosureSEC source: 0000899243-19-017018 · doc4.xml · derivative · entry 1 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The option vests in full on the earlier of June 13, 2020 or the day immediately prior to the company's 2020 annual meeting of shareholders. Read SEC document |
| May 23, 2019 Filed May 28, 2019 21:22 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantStock Option (right to buy) · Derivative | 11,432 | $0.00 Strike: $19.90 | $0.00 |
DisclosureSEC source: 0000899243-19-014971 · doc4.xml · derivative · entry 2 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,432 Underlying: Common Stock · 11,432 shares Expires 2029-05-23 F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 23, 2019 Filed May 28, 2019 21:22 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantCommon Stock, $0.0001 par value | 6,442 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-014971 · doc4.xml · nonDerivative · entry 1 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,192 F1 · shares: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2020 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 22, 2019 Filed May 24, 2019 16:05 UTC | Axcella Health Inc. AXLA · Entity 116059 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $14.28 | $0.00 |
DisclosureSEC source: 0001104659-19-031783 · a4.xml · derivative · entry 1 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2029-05-21 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 01:02 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $9.09 | $0.00 |
DisclosureSEC source: 0000899243-18-018513 · doc4.xml · derivative · entry 1 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-25 F1 · derivative.exercise_date: The option vests in full on the earlier of June 26, 2019 or the day immediately prior to the company's 2019 annual meeting of shareholders. Read SEC document |
| May 23, 2018 Filed May 24, 2018 17:08 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $32.79 | $0.00 |
DisclosureSEC source: 0000899243-18-013930 · doc4.xml · derivative · entry 2 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-05-23 F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| May 23, 2018 Filed May 24, 2018 17:08 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantCommon Stock, $0.0001 par value | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-013930 · doc4.xml · nonDerivative · entry 1 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 F1 · shares: These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2019 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 21:09 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $11.21 | $0.00 |
DisclosureSEC source: 0000899243-17-016854 · doc4.xml · derivative · entry 1 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-19 F1 · derivative.exercise_date: The option vests in full on the earlier of June 20, 2018 or the day immediately prior to the company's 2018 annual meeting of shareholders. Read SEC document |
| May 25, 2017 Filed May 30, 2017 16:05 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $18.26 | $0.00 |
DisclosureSEC source: 0000899243-17-014688 · doc4.xml · derivative · entry 1 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2027-05-25 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2018 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date. Read SEC document |
| November 23, 2016 Filed Nov 28, 2016 16:05 UTC | Aimmune Therapeutics, Inc. AIMT · Entity 145931 | GrantStock Option (right to buy) · Derivative | 39,510 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0000899243-16-034428 · doc4.xml · derivative · entry 1 Behar Gregory · CIK 0001643766 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,510 Underlying: Common Stock · 39,510 shares Expires 2026-11-22 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable with respect to 1/36th of the total number of shares subject to the option in successive, equal monthly installments measured from November 23, 2016, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.